Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.64 |
| ▸ | TK2 | O00142 | 2/20 | 0.59 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600800 | 1.00 | PYGM (0.64) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16152124 | 0.88 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2754231 | 0.87 | PYGM (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2754232 | 0.87 | PYGM (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28299287 | 0.87 | PYGM (0.58) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL17372249 | 0.86 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16152125 | 0.86 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL22028243 | 0.84 | PYGM (0.67) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL41703 | 0.84 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512877 | 0.84 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3750544-B1 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | UNIV EMORY (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
| US-20010009906-A1 | Use of 3'-azido-2' ,3' -dideoxyuridine | SCHINAZI RAYMOND F (US) | 2001-07-26 | — | — | US | disclosed |
| EP-1089741-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6194391-B1 | CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION | EMORY UNIVERSITY | 2001-02-27 | — | — | US | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000043014-A2 | BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999066936-A9 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | UNIV EMORY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0986375-A2 | USE OF MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | Triangle Pharmaceuticals Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998044913-A2 | COMPOSITIONS CONTAINING MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | TRIANGLE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PYGM 449/4885TK2 91/4885SLC28A1 262/4885 |
| US-20010009906-A1 | Use of 3'-azido-2' ,3' -dideoxyuridine | NSUN2, DUT, DUS2 | PYGM 3949/4885TK2 82/4885SLC28A1 311/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PYGM 449/4885TK2 91/4885SLC28A1 262/4885 |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | PYGM 715/4885TK2 89/4885SLC28A1 86/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PYGM 694/4885TK2 70/4885SLC28A1 260/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PYGM 694/4885TK2 70/4885SLC28A1 260/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PYGM 715/4885TK2 89/4885SLC28A1 86/4885 |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PYGM 715/4885TK2 89/4885SLC28A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.